港股百奥赛图-B（02315）今日盘中大涨8.81%，引发市场广泛关注。截至下午3点28分，该股报价25.56港元，成交量达56.35万股，总成交额1402万港元。
消息面上，百奥赛图-B近日发布2025年上半年业绩报告，显示公司业绩大幅改善。报告期内，集团收益达人民币6.21亿元，同比增长51.3%；股东应占溢利4799.9万元，实现扭亏为盈；每股盈利0.12元。其中，以创新动物模型销售为核心的临床前产品与服务业务收入增长56.9%至人民币4.58亿元，毛利率维持在约70%的高水平。另一核心业务抗体发现业务收入同比增长37.8%至人民币1.63亿元，毛利率更高达约90%。
分析指出，百奥赛图凭借全球领先的基因编辑技术，成功构建了以创新动物模型和抗体分子转让开发为核心的双引擎增长模式。公司通过RenMice系列全人抗体小鼠平台、"千鼠万抗"计划及全球化的专利网络，已在技术和专利层面构筑起双重护城河，形成难以复制的竞争壁垒。随着百奥赛图逐步确立其"全球新药发源地"的行业地位，其长期成长价值和投资吸引力持续提升，这也是今日股价大涨的重要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.